[Mifepristone--a controversial drug with great potential].

article OA: closed CC0
View on OpenAlex View on PubMed

Abstract

BACKGROUND: Antiprogestins, agents that inhibit the action of progesterone, are among the most controversial and yet the more interesting therapeutic compounds developed over the past 20 years. MATERIAL AND METHODS: We present a review of the literature identified through limited searches on Medline, Cochrane and the Internet, with a discussion of the biological, clinical, political and ethical aspects of this important drug. RESULTS: The first effective antiprogestin in clinical use was mifepristone (also known as RU 486). This agent provides the most effective and safest means of medical abortion. It may also be used as a contraceptive and delivery-inducing agent and in the treatment of spontaneous abortion, ectopic pregnancies, leiomyoma, endometriosis, intrauterine fetal death, Cushing's syndrome and progesterone-dependent malignancies. INTERPRETATION: The introduction of mifepristone as an abortion-inducing agent has created intense political, ethical and moral controversies which have delayed clinical investigations and evaluations for potential expanded use.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Hormone Antagonists Hormone Antagonists Hormone Antagonists Mifepristone Mifepristone Mifepristone Mifepristone Female Genital Diseases, Female Genital Diseases, Female History, 20th Century Humans Labor, Induced

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:13.417725+00:00
License: CC0 · commercial use OK